Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate

Overview

Journal J Bone Metab

Date 2014 Jul 16

PMID 25025002

Citations 9

Authors

Yougun Won

Joon-Ryul Lim

Young-Hwan Kim

Hyung-Keun Song

Kyu Hyun Yang

Affiliations

Soon will be listed here.

Abstract

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.

Citing Articles

Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review.

Tarantino U, Cariati I, Greggi C, Iundusi R, Gasbarra E, Iolascon G Osteoporos Int. 2022; 33(12):2467-2478.

PMID: 35851407 DOI: 10.1007/s00198-022-06482-z.

Osteonecrosis of the Jaw and Bilateral Atypical Femoral Fracture Both Occurring During Treatment for Osteoporosis: A Case Report.

Payumo E, Cudal B, Crisostomo T J ASEAN Fed Endocr Soc. 2021; 33(2):194-198.

PMID: 33442127 PMC: 7784155. DOI: 10.15605/jafes.033.02.13.

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database.

Toriumi S, Kobayashi A, Uesawa Y Pharmaceuticals (Basel). 2020; 13(12).

PMID: 33339150 PMC: 7765621. DOI: 10.3390/ph13120467.

Osteonecrosis of the Jaw and Concomitant Atypical Femoral Fractures with Bisphosphonates: A Comprehensive Literature Review.

Aravamudan V, Er C Cureus. 2019; 11(7):e5113.

PMID: 31523544 PMC: 6741378. DOI: 10.7759/cureus.5113.

Oral Bisphosphonate Induced Recurrent Osteonecrosis of Jaw with Atypical Femoral Fracture and Subsequent Mandible Fracture in the Same Patient: A Case Report.

Pispati A, Pandey V, Patel R J Orthop Case Rep. 2018; 8(3):85-88.

PMID: 30584526 PMC: 6298721. DOI: 10.13107/jocr.2250-0685.1124.

References

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

Giusti A, Hamdy N, Papapoulos S . Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone. 2010; 47(2):169-80. DOI: 10.1016/j.bone.2010.05.019. View

Salesi N, Pistilli R, Marcelli V, Govoni F, Bozza F, Bossone G . Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Res. 2006; 26(4B):3111-5. View

Dell R, Adams A, Greene D, Funahashi T, Silverman S, Eisemon E . Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27(12):2544-50. DOI: 10.1002/jbmr.1719. View

Seraphim A, Al-Hadithy N, Mordecai S, Al-Nammari S . Do bisphosphonates cause femoral insufficiency fractures?. J Orthop Traumatol. 2012; 13(4):171-7. PMC: 3506831. DOI: 10.1007/s10195-012-0207-x. View

Khosla S, Burr D, Cauley J, Dempster D, Ebeling P, Felsenberg D . Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10):1479-91. DOI: 10.1359/jbmr.0707onj. View

Allen M, Burr D . Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone. 2010; 49(1):56-65. DOI: 10.1016/j.bone.2010.10.159. View

Unnanuntana A, Saleh A, Mensah K, Kleimeyer J, Lane J . Atypical femoral fractures: what do we know about them?: AAOS Exhibit Selection. J Bone Joint Surg Am. 2013; 95(2):e8 1-13. DOI: 10.2106/JBJS.L.00568. View

Almasan H, Baciut M, Rotaru H, Bran S, Almasan O, Baciut G . Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases. Rom J Morphol Embryol. 2011; 52(4):1233-41. View

10.

Meier R, Perneger T, Stern R, Rizzoli R, Peter R . Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012; 172(12):930-6. DOI: 10.1001/archinternmed.2012.1796. View

11.

Kalyan S, Quabius E, Wiltfang J, Monig H, Kabelitz D . Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res. 2012; 28(4):728-35. DOI: 10.1002/jbmr.1769. View

12.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. DOI: 10.1016/j.joms.2009.01.009. View

13.

Shane E, Burr D, Abrahamsen B, Adler R, Brown T, Cheung A . Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2013; 29(1):1-23. DOI: 10.1002/jbmr.1998. View

14.

Pazianas M, Miller P, Blumentals W, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29(8):1548-58. DOI: 10.1016/j.clinthera.2007.08.008. View

15.

Park-Wyllie L, Mamdani M, Juurlink D, Hawker G, Gunraj N, Austin P . Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305(8):783-9. DOI: 10.1001/jama.2011.190. View

16.

Reid I . Osteonecrosis of the jaw: who gets it, and why?. Bone. 2008; 44(1):4-10. DOI: 10.1016/j.bone.2008.09.012. View

17.

. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76. DOI: 10.1016/j.joms.2006.11.003. View

18.

Feldstein A, Black D, Perrin N, Rosales A, Friess D, Boardman D . Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012; 27(5):977-86. DOI: 10.1002/jbmr.1550. View

19.

Hewitt C, Farah C . Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007; 36(6):319-28. DOI: 10.1111/j.1600-0714.2007.00540.x. View